WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results